Adagio Medical

Adagio Medical is a clinical-stage medical device innovator targeting the large and growing market for atrial fibrillation ablation. Its core technology is the Adagio System, which utilizes an ultra-low temperature cryoablation (ULTC) approach with a linear catheter designed to create durable, continuous lesions in cardiac tissue. The company is advancing its lead program through clinical studies, positioning itself as a potential competitor in the pulsed field ablation (PFA) and cryoablation landscape. Backed by venture capital, Adagio aims to address limitations of current thermal ablation technologies by offering a safer, more effective, and efficient solution for electrophysiologists.

Ultra-Low Temperature Cryoablation (ULTC) platform using a linear catheter to create contiguous, transmural lesions for cardiac tissue ablation.

Adagio Medical competes in the cardiac ablation market against major players like Medtronic (cryoablation, RF, PFA), Johnson & Johnson's Biosense Webster (RF, PFA), Boston Scientific (RF, PFA), and Abbott (RF). The recent emergence of Pulsed Field Ablation (PFA) as a potentially disruptive, non-thermal technology represents a particularly significant competitive threat, setting a high bar for safety and efficacy that new thermal technologies must meet or exceed.